Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SI-B001 + SI-B003 with or without chemotherapy in advanced or metastatic non-small cell lung cancer
CTR20232081Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab, SI-B003 in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
izalontamabSI-B003
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232081.